Across TCGA pan-cancer cohorts, PRR16 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PRR16 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRR16 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRR16 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where PRR16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.952	0.433	.005	14	view →
PDAC	DFS	Quartile	II,III,IV	1.000	0.493	.026	3	view →
LSCC	OS	Tertile	All	0.573	0.909	.011	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PRR16 tumor-vs-normal RNA expression · all PRR16 data types